Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
12 08 2022
Historique:
received: 26 04 2021
pubmed: 12 9 2021
medline: 17 8 2022
entrez: 11 9 2021
Statut: ppublish

Résumé

Several chemical compounds including natural products have been suggested as being effective against age-related diseases or as beneficial for a healthy life. On the other hand, forkhead box O (FOXO) proteins are emerging as key cellular components associated with extreme human longevity. FOXO proteins are mainly regulated by posttranslational modifications and as these modifications are reversible, activation and inactivation of FOXO are attainable through pharmacological treatment. Here, we questioned whether a panel of compounds with known health-beneficial properties has the capacity to induce the activity of FOXO factors. We show that resveratrol, a phytoalexin present in grapes and other food products, the amide alkaloid piperlongumine found in the fruit of the long pepper, and the plant-derived β-carboline compound harmine induced nuclear translocation of FOXO3. We also show that piperlongumine and harmine but not resveratrol activate FOXO-dependent transcription. We determined the half maximal effective concentration (EC50) values for resveratrol, piperlongumine, and harmine for FOXO translocation, and analyzed their inhibitory impact on chromosomal maintenance 1 (CRM1)-mediated nuclear export and the production of reactive oxygen species (ROS). We also used chemical biology approach and Western blot analysis to explore the underlying molecular mechanisms. We show that harmine, piperlongumine, and resveratrol activate FOXO3 independently of phosphoinositide 3-kinase (PI3K)/AKT signaling and the CRM1-mediated nuclear export. The effect of harmine on FOXO3 activity is at least partially mediated through the inhibition of dual-specificity tyrosine (Y) phosphorylationregulated kinase 1A (DYRK1A) and can be reverted by the inhibition of sirtuins (SIRTs).

Identifiants

pubmed: 34508571
pii: 6368778
doi: 10.1093/gerona/glab265
pmc: PMC9373959
doi:

Substances chimiques

Dioxolanes 0
FOXO3 protein, human 0
Forkhead Box Protein O3 0
Karyopherins 0
Receptors, Cytoplasmic and Nuclear 0
Harmine 4FHH5G48T7
Proto-Oncogene Proteins c-akt EC 2.7.11.1
piperlongumine SGD66V4SVJ
Resveratrol Q369O8926L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1485-1493

Subventions

Organisme : Fundação para a Ciência e a Tecnologia
ID : UID/BIM/04773/2013
Organisme : Centre for Biomedical Research
Organisme : Spanish Ministry of Science, Innovation and Universities
ID : RTI2018-094629-B-I00
Organisme : Deutsche Forschungsgemeinschaft
ID : BR1034/6-1

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America.

Références

J Mol Signal. 2010 Jul 19;5:10
pubmed: 20642839
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Methods Mol Biol. 2019;1890:1-9
pubmed: 30414140
Cancers (Basel). 2020 Dec 09;12(12):
pubmed: 33316942
Nat Rev Drug Discov. 2021 Jan;20(1):21-38
pubmed: 33173189
Biochim Biophys Acta. 2015 Jun;1852(6):1114-23
pubmed: 25315298
Biochem J. 2000 Jul 15;349(Pt 2):629-34
pubmed: 10880363
J Biomol Screen. 2014 Jan;19(1):57-65
pubmed: 24045581
Mar Drugs. 2020 Jul 05;18(7):
pubmed: 32635607
Molecules. 2020 Dec 16;25(24):
pubmed: 33339338
Gerontology. 2015;61(6):515-25
pubmed: 25832544
Hum Mol Genet. 2009 Dec 15;18(24):4897-904
pubmed: 19793722
BMC Cell Biol. 2009 Feb 25;10:14
pubmed: 19243599
FEBS J. 2009 Nov;276(21):6324-37
pubmed: 19796173
Nat Rev Mol Cell Biol. 2013 Feb;14(2):83-97
pubmed: 23325358
Aging Cell. 2016 Apr;15(2):196-207
pubmed: 26643314
J Neurosci. 1998 Jun 1;18(11):4042-9
pubmed: 9592085
Oncogene. 2008 Apr 7;27(16):2276-88
pubmed: 18391970
Curr Top Dev Biol. 2018;127:165-192
pubmed: 29433737
Br J Pharmacol. 2017 Jun;174(11):1395-1425
pubmed: 27659301
Int J Cancer. 2017 Dec 15;141(12):2379-2391
pubmed: 28631330
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
pubmed: 16732220
Genetics. 2015 Oct;201(2):613-29
pubmed: 26219299
Biochem J. 2001 May 1;355(Pt 3):597-607
pubmed: 11311120
Oncogene. 2010 May 20;29(20):2973-82
pubmed: 20208562
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13987-92
pubmed: 18765803
J Neurosci. 1996 Feb 15;16(4):1324-36
pubmed: 8778284
Nature. 2019 Jul;571(7764):183-192
pubmed: 31292558
Food Chem Toxicol. 2010 Mar;48(3):839-45
pubmed: 20036304
Assay Drug Dev Technol. 2007 Jun;5(3):333-41
pubmed: 17638533
Curr Biol. 2012 Sep 11;22(17):R741-52
pubmed: 22975005
J Biol Chem. 2005 May 27;280(21):20589-95
pubmed: 15788402
Chembiochem. 2008 Sep 22;9(14):2229-37
pubmed: 18756565

Auteurs

Lucia Jimenez (L)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.

Andreia Silva (A)

Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal.
Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal.
Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal.

Giampaolo Calissi (G)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.

Inês Grenho (I)

Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal.
Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal.
Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal.

Rita Monteiro (R)

Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal.
Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal.
Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal.

Victor Mayoral-Varo (V)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.

Carmen Blanco-Aparicio (C)

Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Joaquin Pastor (J)

Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Victor Bustos (V)

Refoxy Pharmaceuticals GmbH, Berlin, Germany.

Franz Bracher (F)

Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany.

Diego Megías (D)

Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Bibiana I Ferreira (BI)

Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal.
Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal.
Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal.

Wolfgang Link (W)

Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH